Clinical Trials Logo

Eclampsia clinical trials

View clinical trials related to Eclampsia.

Filter by:

NCT ID: NCT06067906 Recruiting - Obesity Clinical Trials

Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients

POPADIPE
Start date: September 14, 2023
Phase: N/A
Study type: Interventional

In view of the known link between pre-eclampsia, overweight/obesity and chronic kidney disease, the aim is to offer for obese and overweight patients to reduce their BMI without reducing lean body mass. The POPADIPE project will make it possible to limit overweight or obesity by means of nutritional management chosen by the patient (hypocaloric or a dissociated diet). The latter has been the subject of little scientific investigation, particularly in relation to the management of post-pre-eclampsia.

NCT ID: NCT06059937 Not yet recruiting - Clinical trials for Patients Hospitalized for Pre-eclampsia

Evaluation of Cardiovascular Risk After Preeclampsia in General Practitioners and Patients

PreCarVasc
Start date: October 2023
Phase:
Study type: Observational

Pre-eclampsia is a disease characterized by placental damage leading to a cascade of complications during pregnancy. It is initially manifested by high blood pressure and the presence of albumin in the urine. It can lead to emergency hospitalization in severe cases and cause major complications or even death in the mother and the fetus. Several studies observing the outcome of patients with pre-eclampsia have shown an increased long-term cardiovascular risk in these patients, justifying regular medical follow-up with the treating physician and specialists, mainly cardiologists. The main objective of this research is to describe the cardiovascular risk assessment actions implemented by the treating general practitioner in the year following pre-eclampsia (blood pressure measurement in the office, self-measurement of blood pressure, ABPM, cardiological consultation, biological monitoring of blood (creatininemia, LDL, fasting glycemia) or urine (albuminurie/creatininurie ratio), and screening and management of possible smoking).

NCT ID: NCT06053203 Not yet recruiting - Clinical trials for Hypertensive Disorders of Pregnancy

Utilization of Aspirin for Prevention of Pre-Eclampsia in Nigeria: A Explanatory Sequential Mixed Methods Study

Start date: September 2023
Phase:
Study type: Observational

The goal of this study is to evaluate the use of aspirin for the prevention of preeclampsia among moderate -to- high-risk pregnant women in tertiary care hospitals in Nigeria followed by a qualitative study to evaluate the barriers and facilitators of aspirin use in prenatal care for the prevention of preeclampsia in Nigeria. The main question[s] it aims to answer are: 1. Is Aspirin used for the prevention of preeclampsia among pregnant women in Nigeria? 2. What factors promote or prevent the utilization of Aspirin for preeclampsia prevention among pregnant women in Nigeria.

NCT ID: NCT06020378 Not yet recruiting - Pre-Eclampsia Clinical Trials

Hydroxychloroquine May be Beneficial for Preeclampsia

Start date: December 1, 2023
Phase:
Study type: Observational

The purpose of this research is to investigate the impact of hydroxychloroquine on the incidence of hypertensive pregnancy disorders in women with a history of recurrent spontaneous abortion (RSA).

NCT ID: NCT06002971 Recruiting - Pregnancy Related Clinical Trials

CONNEQT Pulse Validation Study

Start date: August 21, 2023
Phase:
Study type: Observational

The purpose of this study is to validate the accuracy of the CONNEQT Pulse blood pressure monitoring system for the measurement of blood pressure as compared to a gold standard, auscultatory sphygmomanometer in a pregnant population.

NCT ID: NCT05924061 Completed - Pre-Eclampsia Clinical Trials

The Role of Pentraxin 3 and Cathepsin B Levels in Preeclamptic Pregnancy

Start date: January 1, 2022
Phase:
Study type: Observational [Patient Registry]

In this study, the investigator aim was to compare Cathepsin B and Pentraxin 3 levels measured from maternal serum of pregnant women diagnosed with preeclampsia in the second trimester, the effects of these levels on maternal/ fetal outcomes and the composite results of Cathepsin B and Pentraxin 3 levels alone or together and contribute to the literature in this area.

NCT ID: NCT05888896 Recruiting - Mild Pre-eclampsia Clinical Trials

Effect of Foot Reflexology on Preeclampsia

Start date: June 9, 2023
Phase: N/A
Study type: Interventional

the aim of this study to investigate the effect of foot reflexology on mild preeclampsia during pregnancy

NCT ID: NCT05863962 Recruiting - Clinical trials for Pre-Eclampsia; Complicating Pregnancy

Comparative Effects of Jacobson's Relaxation Techniques and Stretching Exercises in Preeclampsia

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

To compare the effect of Jacobson's Relaxation Techniques and stretching exercises on Preeclampsia in pregnant women.

NCT ID: NCT05847361 Completed - Acute Renal Failure Clinical Trials

BH4 Blood Levels Variations in Pre Eclamptic Women

BH4P
Start date: March 15, 2023
Phase:
Study type: Observational

tetrahydrobiopterin (BH4) is degraded by several enzymes, including BH4 oxidase and peroxidases. Several factors can affect its synthesis and degradation. BH4 deficiency or depletion and genetic variations in the genes involved in BH4 metabolism have been associated with hypertension, suggesting that BH4 may play a role in the pathogenesis of hypertension. The maternity center of Tunis ( CMNT ) is a level 3 maternity center, supporting over 12 000 births yearly, where the caesarean section's rate is very high, close to 45% of deliveries. Early detection of these patients can help control maternal and neonatal safety outcomes. we can avoid complications such as severe preeclampsia, HELLP syndrom and eclampsia for the mother, and preterm delievery and fetal growth restriction for the new born. in the literature, studies have reported a decrease in BH4 levels in pregnant women compared to non-pregnant women and others showed that its deficiency or depletion has been associated with hypertension. Moreover, tetrahydrobiopterin administration has been studied as a potential treatment for preeclampsia but the optimal dose has not yet been determined, and further studies are needed to determine the appropriate dose, timing, and duration of BH4 supplementation in this context. Thus, BH4 blood levels as a mean of screening, could enrich our diagnostic arsenal. The purpose of our study is to compare BH4 levels between preeclamptic and normotensive women.

NCT ID: NCT05816044 Completed - Pre-Eclampsia Clinical Trials

Evaluation of HALP Score in Preeclampsia

Start date: February 22, 2023
Phase:
Study type: Observational

Preeclampsia is a serious condition that can occur during pregnancy and can pose problems for both the mother and the baby. It occurs in approximately 2-8% of all pregnancies globally and is caused by issues with blood vessels, leading to elevated blood pressure and other related health concerns. Additionally, insufficient nutrition and inflammation within the mother's body may contribute to the development of preeclampsia. The HALP score serves as a tool to assess various elements within the blood, indicating inflammation or inadequate nutrition. Although it has been utilized in other medical contexts, its application during pregnancy remains limited. The HALP score has been employed to predict the emergence of ailments such as heart disease and cancer. Given that preeclampsia can stem from inflammation and poor nutrition, the potential of the HALP score in predicting the likelihood of preeclampsia during pregnancy is being examined through research.